secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-098783
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics appoints Christopher Hite to Board of Directors
-----------------------------------------------------------------

- Christopher Hite appointed as Class III Director effective March 5, 2026.
- Initial option grant for 24,937 shares at $38.85, vesting monthly over three years.
- Annual cash retainer of $45,000, pro-rated for 2026.
- Eligible for annual option grants from 2027: lesser of 18,000 shares or up to $400k in grant date fair value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526098783/0001193125-26-098783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526098783/vera-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-098783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer